# Phase 2b Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 mg/g Compared to Delgocitinib Cream Vehicle Over a 16-week Treatment Period in Adult Subjects With Chronic Hand Eczema

> **NCT03683719** · PHASE2 · COMPLETED · sponsor: **LEO Pharma** · enrollment: 258 (actual)

## Conditions studied

- Chronic Hand Eczema

## Interventions

- **DRUG:** Delgocitinib cream
- **DRUG:** Delgocitinib cream vehicle

## Key facts

- **NCT ID:** NCT03683719
- **Lead sponsor:** LEO Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-11-28
- **Primary completion:** 2020-03-06
- **Final completion:** 2020-04-20
- **Target enrollment:** 258 (ACTUAL)
- **Last updated:** 2025-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03683719

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03683719, "Phase 2b Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 mg/g Compared to Delgocitinib Cream Vehicle Over a 16-week Treatment Period in Adult Subjects With Chronic Hand Eczema". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03683719. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*